A5028914408- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Multiple Myeloma Research and Treatments
- Head and Neck Cancer Studies
- Global Cancer Incidence and Screening
- Radiomics and Machine Learning in Medical Imaging
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Breast Cancer Therapies
- Pancreatic and Hepatic Oncology Research
- BRCA gene mutations in cancer
- Breast Lesions and Carcinomas
- Statistical Methods in Clinical Trials
- Colorectal Cancer Screening and Detection
- Peptidase Inhibition and Analysis
- Gastric Cancer Management and Outcomes
- Cervical Cancer and HPV Research
- Lung Cancer Treatments and Mutations
- AI in cancer detection
- Bladder and Urothelial Cancer Treatments
- Ethics in Clinical Research
- Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- MRI in cancer diagnosis
University of Warwick
2016-2025
Coventry (United Kingdom)
2013-2019
National Institute for Health Research
2016-2019
Mount Vernon Cancer Centre
2012-2019
Cambridge University Hospitals NHS Foundation Trust
2012-2019
University College London
2016-2019
University of Cambridge
2011-2018
National Health Service
2005-2018
Kirin (United States)
2018
University Hospitals Coventry and Warwickshire NHS Trust
2018
The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results European Study Group for Pancreatic Cancer 1 Trial and update interim results.In a multicenter trial using two-by-two factorial design, we randomly assigned 73 patients with resected ductal adenocarcinoma to chemoradiotherapy alone (20 Gy over two-week period plus fluorouracil), 75 chemotherapy (fluorouracil), 72 both chemotherapy, 69 observation.The analysis was based 237 deaths among...
Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was to assess if an oral factor Xa inhibitor, rivaroxaban, would offer alternative VTE Patient and Methods In multicenter, randomized, open-label, pilot trial the United Kingdom, active cancer who had symptomatic pulmonary embolism (PE), incidental PE, or lower-extremity proximal deep vein...
BackgroundThe incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed for treatment de-escalation in this setting to reduce the toxicity standard cisplatin treatment, but no randomised evidence exists efficacy strategy.MethodsWe did open-label controlled phase 3 trial at 32 head and neck centres Ireland, Netherlands, UK, patients aged 18...
Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned GEM alone or plus capecitabine (GEM-CAP).Patients with previously untreated histologically cytologically proven locally metastatic carcinoma pancreas a performance status <or= 2 were recruited. Patients GEM-CAP. The primary outcome measure survival. Meta-analysis published studies also...
To assess the influence of resection margins on survival for patients with resected pancreatic cancer treated within context adjuvant European Study Group Pancreatic Cancer-1 (ESPAC-1) study.Pancreatic is associated a poor long-term rate only 10% to 15% after resection. Patients positive microscopic (R1) have worse survival, but it not known how they fare in studies.ESPAC-1, largest randomized study resectable ever performed, set out look at roles chemoradiation and chemotherapy....
Community-based approaches to healthcare improvement are receiving increasing attention.Such could offer an infrastructure for efficient knowledge-sharing and a potent means of influencing behaviours, but their potential is yet be optimised.After briefly reviewing challenges communitybased approaches, we describe in detail the clinical community model.Through exploring communities practice, seek identify practical lessons optimising this community-based approach improvement.Through...
The role of image-guided surveillance as compared with planned neck dissection in the treatment patients squamous-cell carcinoma head and who have advanced nodal disease (stage N2 or N3) received chemoradiotherapy for primary is a matter debate.
Early mortality in multiple myeloma (MM) is usually attributed to combined effects of active disease and comorbid factors. We have studied early deaths a series large multicenter trials assess direct causes death, their predictability, whether current management strategies reduced frequency.A total 3,107 newly diagnosed patients entered onto United Kingdom Medical Research Council MM from 1980 2002 were studied. Trial files, final clinical summaries, postmortem reports analyzed.Death within...
Breast cancers are complex ecosystems of malignant cells and the tumour microenvironment
BackgroundPrevious studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate relationship RCB with long-term prognosis across different phenotypic subtypes breast cancer, assess generalisability broad range practice settings.MethodsIn this analysis, 12 institutes and trials Europe USA were identified by personal communications...
BackgroundAdjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant non-inferior the 12-month regarding disease-free survival.MethodsThis study an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres in UK. randomly assigned cancer,...
Background: Previous reports identifying discordance between multiparameter tests at the individual patient level have been largely attributed to methodological shortcomings of multiple in silico studies. Comparisons tests, when performed using actual diagnostic assays, predicted demonstrate high degrees concordance. OPTIMA prelim compared risk stratification and subtype classification different directly on same population. Methods: Three hundred thirteen women with early breast cancer were...
The frequency of mammographic surveillance for women after diagnosis breast cancer varies globally. aim this study was to evaluate whether less than annual mammography non-inferior in terms cancer-specific survival aged 50 years or older. Mammo-50 a multicentre, randomised, phase 3 trial versus frequent (2-yearly conservation surgery; 3-yearly mastectomy) older at initial invasive non-invasive and who were recurrence free post curative surgery. conducted 114 National Health Service hospitals...
In patients with multiple myeloma, despite a major reduction of bone pain achieved chemotherapy, skeletal disease continues to progress. The effects clodronate, an inhibitor osteoclastic resorption, are evaluated on the natural history in newly diagnosed myeloma. Within framework VIth MRC Multiple Myeloma Trial, 536 (218 women, 318 men) recently myeloma were randomized receive either clodronate 1600 mg daily ( n =264) or outwardly identical placebo =272) addition chemotherapy. Treatment was...
Background: Cigarette smoking is the most consistently reported risk factor for pancreas cancer, yet dose-response relationship in many cancer studies weak. Because of poor prognosis case-control have been based largely on interviews with proxy respondents, who are known to report less reliable information detailed habits than original subjects. Purpose : Our purpose was evaluate cigarette as a data obtained only from direct and estimate effects quitting switching nonfiltered filtered...
The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial examined efficacy of anthracyclines in adjuvant treatment early breast cancer.In NEAT, we compared four cycles epirubicin followed by cyclophosphamide, methotrexate, fluorouracil (CMF) with six CMF alone. In trial, CMF, eight alone every 3 weeks. primary end points were relapse-free overall survival. secondary adverse effects, dose intensity, quality life.The two trials included 2391 women cancer; median follow-up was 48...
Following 2 pilot studies which showed 57 and 61% response rates to intravenous cisplatin for transitional cell carcinoma of the bladder prior definitive treatment, West Midlands Urological Research Group (WMURG) Australian Bladder Cancer Study (ABCSG) independently began randomised trials test survival benefit neo-adjuvant radiotherapy in T2-T4 M0 bladder. Both failed recruit their target numbers 250 patients 320 Australia. Since they had similar treatment protocols eligibility criteria,...
Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict relapse and survival in melanoma.
The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment early breast cancer. We investigated prospectively predictive biomarkers anthracycline including HER2 TOP2A.
BackgroundMyeloma causes profound immunodeficiency and recurrent, serious infections. Around 5500 new cases of myeloma are diagnosed per year in the UK, a quarter patients will have infection within 3 months diagnosis. We aimed to assess whether newly with benefit from antibiotic prophylaxis prevent infection, investigate effect on antibiotic-resistant organism carriage health care-associated infections myeloma.MethodsTEAMM was prospective, multicentre, double-blind, placebo-controlled...